Abstract
2018 saw the failure of several large clinical trials that were based on the premise that reduction of amyloid-β levels is an effective treatment for symptomatic Alzheimer disease. Yet, over the same time period, good news also emerged about the diagnostic value of tau PET imaging.
Original language | English (US) |
---|---|
Pages (from-to) | 61-62 |
Number of pages | 2 |
Journal | Nature Reviews Neurology |
Volume | 15 |
Issue number | 2 |
DOIs |
|
State | Published - Feb 1 2019 |
ASJC Scopus subject areas
- Clinical Neurology
- Cellular and Molecular Neuroscience